NOS2 Cancer Research Results

NOS2, nitric oxide synthase 2: Click to Expand ⟱
Source:
Type:
Also known as NOS2A, INOS
Nitric Oxide Synthase 2 (NOS2, also known as inducible NOS or iNOS) in cancer.
elevated NOS2 has been shown to predict poor outcome in cancer such as ER- breast cancer, glioma, melanoma, cervical, liver, ovarian, and pancreatic. Taken together, NOS2 may be one of the most powerful biomarker and predictors of poor prognosis and an ideal target for cancer therapy.
Many cancers exhibit upregulated NOS2 expression as part of the tumor-associated inflammatory response.

– Examples include colorectal, breast, lung, and some head and neck cancers, where the inflammatory microenvironment can drive NOS2 induction.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
76- QC,    Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy
- in-vitro, Pca, PC3
aSmase↝, Diablo↑, Fas↓, Hsc70↓, Hif1a↓, Mcl-1↓, HSP90↓, FLT4↓, EphB4↓, DNA-PK↓, PARP1↓, ATM↓, XIAP↝, PLC↓, GnT-V↝, heparanase↝, NM23↑, CSR1↑, SPP1↓, DNMT1↓, HDAC4↓, CXCR4↓, β-catenin/ZEB1↓, FBXW7↝, AMACR↓, cycD1/CCND1↓, IGF-1R↓, IMPDH1↓, IMPDH2↓, HEC1↓, NHE1↓, NOS2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

XIAP↝, 1,  

Core Metabolism/Glycolysis ⓘ

AMACR↓, 1,  

Cell Death ⓘ

aSmase↝, 1,   CSR1↑, 1,   Diablo↑, 1,   Fas↓, 1,   Mcl-1↓, 1,  

Transcription & Epigenetics ⓘ

SPP1↓, 1,  

Protein Folding & ER Stress ⓘ

Hsc70↓, 1,   HSP90↓, 1,  

DNA Damage & Repair ⓘ

ATM↓, 1,   DNA-PK↓, 1,   DNMT1↓, 1,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

FBXW7↝, 1,   HDAC4↓, 1,   IGF-1R↓, 1,  

Migration ⓘ

EphB4↓, 1,   GnT-V↝, 1,   heparanase↝, 1,   NM23↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

FLT4↓, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,  

Cellular Microenvironment ⓘ

PLC↓, 1,  

Clinical Biomarkers ⓘ

HEC1↓, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

IMPDH1↓, 1,   IMPDH2↓, 1,  
Total Targets: 32

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: NOS2, nitric oxide synthase 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:409  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page